Overall survival also extended with conjugate treatment In a small, phase II trial, patients with advanced gastric cancer were far more likely to respond to conjugate therapy with trastuzumab deruxtecan (Enhertu) than with...
Read MoreHERO findings also confirm fewer cardiovascular events with relugolix More than 96% of men with advanced prostate cancer who were treated with relugolix, an oral, highly selective gonadatropin-releasing hormone (GnRH)...
Read More
FRIDAY, May 29, 2020 (HealthDay News) — For men with advanced prostate cancer, the oral...
Read MoreTo determine the maximum tolerated dose (MTD) of stereotactic ablative radiotherapy (SABR) in combination with immunotherapy for the treatment of metastatic melanoma. The study also investigates the effects of timing and dosing...
Read MoreThe chemical constituents of the roots and bark of Azadirachta indica were investigated, leading to the isolation of six tricyclic diterpenoids and four limonoids including a new compound, azadirachtin J (4). The structures were...
Read MoreThe widely used in vitro invasion assays for head and neck squamous cell carcinoma (HNSCC) are wound healing, transwell, and organotypic assays. However, these are still lab-intensive and time-consuming tasks. For the rapid...
Read MoreMelanoma is a very lethal tumor type that easily spreads and colonizes regional and distant tissues. Crucial phenotypic changes that favor melanoma metastasis are interposed by the tumor microenvironment (TME), representing a...
Read More
Few prospective studies on outcomes in CSCC have been performed, and outcomes for patients treated...
Read MoreAlthough previous studies suggest objective responses with BRAF and MEK inhibitors in the majority of patients with BRAF-mutant melanoma, data also suggest that acquired resistance limits response durations with these drugs....
Read More